RETROPHIN, INC. (NASDAQ:RTRX) Files An 8-K Results of Operations and Financial Condition
ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION
release announcing, among other things, its financial results for
the quarter ended March 31, 2017. A copy of the press release and
accompanying information is attached as Exhibit 99.1 to this
current report.
hereto, is being furnished and shall not be deemed filed for the
purposes of Section 18 of the Securities Exchange Act of 1934, as
amended, or otherwise subject to the liabilities of that Section.
The information in this Item 2.02, and Exhibit 99.1 attached
hereto, shall not be incorporated by reference into any
registration statement or other document filed with the
Securities and Exchange Commission, whether filed before or after
the date hereof regardless of any general incorporation language
in any such filing, unless the registrant expressly sets forth in
such filing that such information is to be considered filed or
incorporated by reference therein.
|
99.1
|
Press release of Retrophin, Inc. dated May 4, 2017.
|
About RETROPHIN, INC. (NASDAQ:RTRX)
Retrophin, Inc. is a biopharmaceutical company focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. It sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria. Its product candidates include Sparsentan, RE-024, RE-034 and NGLY1. RETROPHIN, INC. (NASDAQ:RTRX) Recent Trading Information
RETROPHIN, INC. (NASDAQ:RTRX) closed its last trading session down -0.02 at 18.72 with 185,688 shares trading hands.
